Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: Using cefoperazone as a test case

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 2, 1999, Pages 81-94

  Strom, Brian L ^a   Schinnar, Rita ^b   Gibson, Gene A ^b   Brennan, P J ^b   Berlin, Jesse A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

Cefoperazone; Hypoprothrombinaemia; Pharmacoepidemiology; Retrospective cohort study

Indexed keywords

ANTIBIOTIC AGENT; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; HEMOGLOBIN; VITAMIN K GROUP;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HYPOPROTHROMBINEMIA; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; RISK; SCHOOL CHILD; UNITED STATES;

EID: 0032902952     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G     Document Type: Article

References (24)

1. Fainstein, V., Bodey, G. P., McCredie, K. B., et al. Coagulation abnormalities induced by β-lactam antibiotics in cancer patients. J. Infect. Dis. 1983; 148: 745-750.
2. Morris, D., Fabricius, D. J., Ambrose, N. S., Scammell, B., Nurdon, D. W. and Keighley, M. R. A high incidence of bleeding is observed in a trial to determine whether addition of metronidazole is needed with latamoxef for prophylaxis in colorectal surgery. J. Hasp. Infect. 1984; 5: 398-408.
3. Schentag, J. J., Welage, L. S., Grasela, T. H. and Adelman, M. H. Determinants of antibiotic-associated hypoprothrombinemia. Pharmacotherapy 1987; 7: 80-86.
4. Schentag, J. J., Wels, P. B., Reitberg, D. P., Walczak, P., Van Tyle, J. H. and Lascola, R. J. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Ann. Surgery 1983; 198: 35-41.
5. Lipsky, J. J. N-methyl-thio-tetrazole inhibitor of the gamma carboxylation of glutamic acid: Possible mechanism for antibiotic-induced hypoprothrombinemia. Lancet 1983; 2: 192-193.
6. Brown, R. B., Klar, J., Lemeshow, S., Teres, D., Pastides, H. and Sands, M. Enhanced bleeding with cefoxitin or moxalactam: statistical analysis within a defined population of 1493 patients. Arch. Intern. Med. 1986; 146: 2159-2164.
7. Grasela, T. H., Walawander, C. A., Welage, L. S., Wing, E., Scarafoni, D. J. and Caldwell, J. W. Prospective surveillance of antibiotic-associated coagulopathy in 970 patients. Pharmacotherapy 1989; 9: 158-164.
8. Shearer, M. J., Bechtold, H., Andrassy, K., et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J. Clin. Pharmacol. 1988; 28: 88-95.
9. Sattler, F. R., Weitekamp, M. R. and Ballard, J. O. Potential for bleeding with the new beta-lactam antibiotics. Ann. Intern. Med. 1986; 105: 924-931.
10. Agnelli, G., Del Favero, A., Parise, P., et al. Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit? Antimicrob. Agents Chemother. 1986; 29: 1108-1109.
11. Baxte, J. G., Marble, D. A., Whitfield, R., Wels, P. B., Walczak, P. and Schentag, J. J. Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycin. Ann. Surg. 1985; 201: 96-102.
12. Goss, T. F., Walawander, C. A., Grasela, T. H. Jr., Meisel, S., Katona, B. and Jaynes, K. Prospective evaluation of risk factors for antibiotic-associated bleeding in critically ill patients. Pharmacotherapy 1992; 12: 283-291.
13. Cohen, M. S., Washton, H. E., Ba, O. and Ranco, S. F. Multicenter clinical trial of cefoperazone sodium in the United States. Am. J. Med. 1984; 77: 35-41.
14. Breslow, N. Odds ratio estimators when the data are sparse. Biometrika 1981; 68: 73-84.
15. Fleis, J. L. In: Statistical Methods for Rates and Proportions, John Wiley & Sons, New York, 1981, pp. 59-75.
16. Mantel, N. and Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst. 1959; 22: 719-748.
17. Halperin, M., Blackwelder, W. C. and Verter, J. I. Estimation of the multivariant logistic risk function: a comparison of the discriminate function and maximum likelihood approaches. J. Chronic Dis. 1971; 24: 125.
18. Kleinbaum, D. G., Kupper, L. L. and Morgenstern, H. In: Epidemiologic Research: Principles and Quantitative Methods, Lifetime Learning Publications, London, 1982, pp. 419-475.
19. Miettinen, O. S. Confounding and effect modification. Am. J. Epidemiol. 1974; 100: 350-353.
20. Prentice, R. Use of the logistic model in retrospective studies. Biometrika 1976; 32: 599-606.
21. Maclure, M. and Greenland, S. Tests for trend and dose response: misinterpretations and alternatives. Am. J. Epidemiol. 1992; 135: 96-104.
22. Mantel, N. Extensions of the Mantel-Haenszel procedure. J. Am. Stat. Assoc. 1963; 58: 690-700.
23. Sattler, F. R., Colao, D. J., Caputo, G. M. and Schoolwerth, A. C. Cefoperazone for empiric therapy in patients with impaired renal function. Am. J. Med. 1986; 81: 229-236.
24. Mueller, R. J., Green, D. M. and Phair, J. P. Hypoprothrombinemia associated with cefoperazone therapy. South. Med. J. 1987; 80: 1360-1362.